The Challenges and Opportunities of lncRNAs in Ovarian Cancer Research and Clinical Use [PDF]
, 2020 [Abstract] Ovarian cancer is one of the most lethal gynecological malignancies worldwide because it tends to be detected late, when the disease has already spread, and prognosis is poor.
Barreiro-Alonso, Aida +6 more
core +1 more source
Generation of endogenously tagged E-cadherin cells using gene editing via non-homologous end joining
STAR Protocols, 2023 Summary: We provide a protocol using non-homologous end joining to integrate an oligonucleotide sequence of a fluorescence protein at the CDH1 locus encoding for the epithelial glycoprotein E-cadherin.
Natalie Rimmer +4 more
doaj +1 more source
The next steps in improving the outcomes of advanced ovarian cancer [PDF]
, 2015 Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication.
Blagden, S +3 more
core +1 more source
Human epididymis protein 4 (HE4) in benign and malignant diseases [PDF]
, 2012 Background: Human epididymis protein 4 (HE4) is described as a useful new biomarker in ovarian cancer. As HE4 is neither tumor nor organ specific, we intensively investigated the occurrence of this protein in female and male patients with various benign ...
Anastasi +39 more
core +1 more source
Exosomes promote pre-metastatic niche formation in ovarian cancer. [PDF]
, 2019 Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a
Dean, Dylan C +4 more
core +2 more sources
Ovarian cancer screening [PDF]
Cancer, 1991 Ovarian cancer will kill more women this year than cancer of the uterine corpus and cervix combined. Outcome is stage dependent. At stage IV, the five year survival rate is about 4.5%, but at stage I it may be well over 90%. Overall, regardless of stage, about 30% of women with ovarian cancer will be alive five years after its diagnosis.
T H, Bourne, K, Reynolds, S, Campbell
openaire +5 more sources
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]
, 2016 Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide +4 more
core +2 more sources
Nature Communications, 2019 OPCML is a tumour suppressor gene that is epigenetically silenced in ovarian cancer and is somatically mutated in various cancers. Here, the authors solve the X-ray crystal structure of OPCML and model clinically relevant mutations that could contribute ...
James R. Birtley +17 more
doaj +1 more source
Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. [PDF]
, 2017 PurposeMany women with an elevated risk of hereditary breast and ovarian cancer have previously tested negative for pathogenic mutations in BRCA1 and BRCA2. Among them, a subset has hereditary susceptibility to cancer and requires further testing.
Adams, Sophie B +8 more
core +1 more source
Risk of cancer after assisted reproduction: a review of the available evidences and guidance to fertility counselors [PDF]
, 2018 Infertile women requiring ovarian stimulation and assisted reproduction techniques (ART) are faced with difficult issues. The fear that using hormones could increase their risk of cancer is the most significant.
Codacci-Pisanelli, G +4 more
core +1 more source